We observed synergy of CB-839 with the highly potent mTOR catalytic site inhibitor in breast cancer cell lines suggesting that therapeutic strategies for GLS inhibitors may include combinations with drugs targeting modulators in both pathways. This evidence concerns the gene MTOR and breast carcinoma.